2018年7月10日,
;91(2补充1)
文章
开放获取
皮肤纤维瘤的临床试验设计
阿什利大炮,库尔特Jarnagin,布鲁斯Korf,林c Widemann,丹尼斯·凯西,Hon-Sum Ko,Jaishri o·布莱克利正在,Verma拉德·k .,多米尼克·c·Pichard
第一次出版2018年7月9日,
DOI: https://doi.org/10.1212/WNL.0000000000005790
阿什利大炮
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
库尔特Jarnagin
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
布鲁斯Korf
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
林c Widemann
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
丹尼斯·凯西
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
Hon-Sum Ko
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
Jaishri o·布莱克利正在
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
Verma拉德·k .
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
多米尼克·c·Pichard
的遗传学(交流,B.K.), University of Alabama at Birmingham; BioPharm Tech (K.J.), San Mateo, CA; Pediatric Oncology Branch (B.C.W.) and Dermatology Branch, Center for Cancer Research (D.C.P.), National Cancer Institute, NIH, Bethesda; Division of Oncology Products (D.C.) and Division of Dermatology and Dental Products (H.-S.K.), Food and Drug Administration, Silver Spring; and Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD.
文摘
客观的几个临床试验针对皮肤纤维瘤(cNF)进行;然而,没有一个护理导致有意义的变化。临床试验设计和开发小组的目标是(1)定义关键考虑cNF临床试验的设计,(2)总结现有数据与这些考虑,和(3)提供关于试验设计的关键元素一致建议加快临床治疗cNF的发展。
方法子群,与专家从遗传学、皮肤病、神经学、肿瘤学,和基本的科学,包括学术界、政府研究和监管程序,和行业,回顾发表和首页未发表的临床试验数据cNF皮肤和其他疾病。讨论这些数据导致制定优先级列表问题解决为了为cNF开发高效和有效的临床试验。
结果标识的子群2 cNF的自然历史研究,4优先措施,结果和6 patient-reported结果cNF的潜在功效试验中使用的工具。时间开始干预,病人资格,机制的行动,给药途径,安全监测和监管机构的交互被确定为关键因素时要考虑为cNF设计临床试验。
结论对齐的端点和方法测量和量化的cNF代表cNF治疗发展的当务之急。先进的技术方法和结果工具使用在其他皮肤病可能适用于cNF研究。病人年龄是一个重要因素指导试验设计和临床发展道路。
术语表
- cNF=
- 皮肤纤维瘤;
- hfu=
- 高频超声;
- NF1=
- 神经纤维瘤病1型;
- 10月=
- 光学相干断层扫描;
- 箴=
- patient-reported结果;
- 生命质量=
- 的生活质量;
- 科幻小说=
- 简式
脚注
去首页Neurology.org/N为充分披露。资金信息和披露认为作者相关的,如果有的话,年底提供这篇文章。
这篇文章加工费由约翰霍普金斯神经纤维瘤治疗加速程序。
看到页面S1
看到页面S5
看到页面S14系列
看到页面S21
- 收到了2017年11月1日。
- 接受的最终形式2018年4月13日。
- ©2018年作者(年代)。发表的Wolters Kluwer健康,公司代表美国神经病学学会。首页
这是一个开放的分布式根据文章知识共享归属许可4.0 (CC),它允许无限制的使用、分配和复制在任何媒介,提供最初的工作是正确引用。
信:快速的网络通信
你可能也会感兴趣
广告
提醒我
推荐的文章
- 文章
联系NF1的良性和恶性周边神经鞘肿瘤t·塔克·Wolkenstein j . Revuz et al。
首页神经学,2005年7月25日 - 皮肤纤维瘤
视角的成年人与神经纤维瘤1和皮肤纤维瘤对临床试验
阿什利大炮,帕梅拉·l·多米尼克•c . Pichard Wolters et al。
首页神经学,2021年7月6日 - 文章
皮肤纤维瘤目前临床和病理问题
皮埃尔Wolkenstein尼古拉•Ortonne Jaishri o·布莱克利正在等。
首页神经学、09年7月,2018年 - 成像
成像评价丛状神经纤维瘤病1型纤维瘤根据调查评估
Shivani Ahlawat, k在Ly,劳拉·m·法等。
首页神经学,2021年7月6日